Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
China · Delayed Price · Currency is CNY 7.50
-0.04 (-0.53%)
Jan 30, 2026, 3:00 PM CST
SHA:600223 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 214.11 | 243.53 | 303.39 | 45.46 | 361.9 | 638.67 | Upgrade |
Depreciation & Amortization | 99.51 | 99.51 | 147.76 | 121.6 | 94.03 | 85.99 | Upgrade |
Other Amortization | 14.9 | 14.9 | 10.01 | 8.01 | 7.91 | 8.71 | Upgrade |
Loss (Gain) From Sale of Assets | -0.96 | -0.96 | 0.77 | -0.77 | 0.15 | -0.09 | Upgrade |
Asset Writedown & Restructuring Costs | 0.7 | 0.7 | 2.19 | 4.74 | 4.04 | 1.07 | Upgrade |
Loss (Gain) From Sale of Investments | -63.98 | -63.98 | -214.34 | -116.21 | -201.34 | -219.55 | Upgrade |
Provision & Write-off of Bad Debts | 28.92 | 28.92 | 38.31 | 66.86 | 101.05 | 70.63 | Upgrade |
Other Operating Activities | 85.45 | 78.74 | 162.9 | 684.2 | 335.79 | 96.53 | Upgrade |
Change in Accounts Receivable | 175.89 | 175.89 | 1,861 | 523.12 | 2,032 | -1,285 | Upgrade |
Change in Inventory | -33.91 | -33.91 | -598.86 | 1,899 | 344.74 | 108.94 | Upgrade |
Change in Accounts Payable | -308.12 | -308.12 | -1,228 | -2,238 | 3,760 | 4,960 | Upgrade |
Change in Other Net Operating Assets | - | - | - | - | 5.59 | 6.32 | Upgrade |
Operating Cash Flow | 205.94 | 228.65 | 474.15 | 998.1 | 6,848 | 4,448 | Upgrade |
Operating Cash Flow Growth | -0.80% | -51.78% | -52.49% | -85.42% | 53.96% | - | Upgrade |
Capital Expenditures | -127.28 | -157.22 | -211.37 | -166.11 | -281.53 | -157.07 | Upgrade |
Sale of Property, Plant & Equipment | -0 | 0.33 | 3.89 | 5.7 | 0.61 | 0.58 | Upgrade |
Cash Acquisitions | - | - | - | - | - | -235.44 | Upgrade |
Divestitures | - | 2,982 | 2,641 | - | 33.05 | - | Upgrade |
Investment in Securities | 5.28 | 11.68 | 177.52 | 30.83 | -268.32 | 458.99 | Upgrade |
Other Investing Activities | 51 | 155.85 | 62.69 | 130.81 | 64.38 | 28.16 | Upgrade |
Investing Cash Flow | -71 | 2,993 | 2,673 | 1.24 | -451.81 | 95.23 | Upgrade |
Long-Term Debt Issued | - | 348 | 2,701 | 12,621 | 9,931 | 14,838 | Upgrade |
Total Debt Issued | 382.4 | 348 | 2,701 | 12,621 | 9,931 | 14,838 | Upgrade |
Long-Term Debt Repaid | - | -2,235 | -5,281 | -13,161 | -15,351 | -17,350 | Upgrade |
Total Debt Repaid | -645.5 | -2,235 | -5,281 | -13,161 | -15,351 | -17,350 | Upgrade |
Net Debt Issued (Repaid) | -263.1 | -1,887 | -2,580 | -540.61 | -5,420 | -2,512 | Upgrade |
Issuance of Common Stock | - | - | - | 22.47 | 17.05 | 922.09 | Upgrade |
Common Dividends Paid | -118.6 | -183.57 | -487.96 | -1,175 | -2,015 | -2,267 | Upgrade |
Other Financing Activities | 51.43 | -35.02 | -29.69 | 75.44 | 629.44 | 305.66 | Upgrade |
Financing Cash Flow | -330.28 | -2,106 | -3,097 | -1,618 | -6,789 | -3,551 | Upgrade |
Foreign Exchange Rate Adjustments | 0.03 | -0.23 | -1.01 | 9.82 | -0.41 | -1.54 | Upgrade |
Net Cash Flow | -195.31 | 1,116 | 48.93 | -608.61 | -393.24 | 990.87 | Upgrade |
Free Cash Flow | 78.66 | 71.44 | 262.79 | 831.98 | 6,567 | 4,291 | Upgrade |
Free Cash Flow Growth | 39.09% | -72.82% | -68.41% | -87.33% | 53.04% | - | Upgrade |
Free Cash Flow Margin | 2.08% | 1.79% | 5.74% | 6.42% | 53.12% | 31.51% | Upgrade |
Free Cash Flow Per Share | 0.08 | 0.07 | 0.26 | 0.73 | 6.35 | 4.23 | Upgrade |
Cash Income Tax Paid | 289.81 | 290.52 | 553.18 | 1,099 | 1,786 | 1,339 | Upgrade |
Levered Free Cash Flow | 55.2 | 3,107 | 2,879 | 1,837 | 2,779 | -194.61 | Upgrade |
Unlevered Free Cash Flow | 59.93 | 3,121 | 2,939 | 2,088 | 2,849 | -137.6 | Upgrade |
Change in Working Capital | -172.71 | -172.71 | 23.18 | 184.2 | 6,145 | 3,766 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.